Breaking News: Avidity Biosciences Sets Sights on 2025 for BLA Submission and Launch of Revolutionary Treatments for Rare Muscle Diseases
Breaking News: Avidity Biosciences Sets Sights on 2025 for BLA Submission and Launch of Revolutionary Treatments for Rare Muscle Diseases Description: Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025. On track to complete enrollment in del-desiran HARBOR TM Phase 3 and potential